Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP)

Manchikanti L, Centeno CJ, Atluri S, Albers SL, Shapiro S, Malanga GA, Abd-Elsayed A, Jerome M, Hirsch JA, Kaye AD, Aydin SM, Beall D, Buford D, Borg-Stein J, Buenaventura RM, Cabaret JA, Calodney AK, Candido KD, Cartier C, Latchaw R, Diwan S, Dodson E, Fausel Z, Fredericson M, Gharibo CG, Gupta M, Kaye AM, Knezevic NN, Kosanovic R, Lucas M, Manchikanti MV, Mason RA, Mautner K, Murala S, Navani A, Pampati V, Pastoriza S, Pasupuleti R, Philip C, Sanapati MR, Sand T, Shah RV, Soin A, Stemper I, Wargo BW, Hernigou P. Pain Physician. 2020 Mar;23(2):E85-E131.

Full Text is Freely Available

The American Society of Interventional Pain Physicians released a position statement on bone marrow concentrate therapy in musculoskeletal disorders. The document lists 10 statements. The document covers the impact of musculoskeletal disorders, bone marrow contrate therapy, US FDA regulatory context, impact of bone marrow cells on healing in various tissues, and clinical outcomes.

View 230 other recent position statements, consensus statements, guidelines, and recommendations related to sports medicine.